The use of the medication Heberprot-P with some 290,000 patients, in twenty countries, has demonstrated the possibility of ensuring the healing of open wounds, ischemic ulcers, and those caused by diabetic foot disease, increasing the formation of granulation tissue, and thus reducing the need for amputation. The medicine, created at Cuba’s Genetic Engineering and Biotechnology […]

Cuban enterprise Heber Biotec and U.S. company Mercurio Biotec have agreed to work together to make Heberprot-P – a Cuban developed medication to treat diabetic foot ulcers – available to patients in the U.S., once it has been approved by the country’s Food and Drug Administration (FDA). Given the success of the product and following […]

Cuban enterprise Heber Biotec and U.S. company Mercurio Biotec have agreed to work together to make Heberprot-P —a Cuban developed medication to treat diabetic foot ulcers— available for patients in the U.S., once it has been approved by the country’s Food and Drug Administration (FDA). Given the success of the product and following the Memorandum […]

The Cuban medicine Heberprot-P will begin a clinical evaluation stage in the United States with the aim of reducing the risks of amputation due to diabetic foot ulcer (DFU), business group BioCubaFarma reported today. Following the procedures of the U.S. authority for the use of drugs (the Food and Drug Administration, FDA), once this stage […]